

ABN 79 104 795 922

### **Appendix 4E**

(ASX Listing Rule 4.3A)

# Preliminary Final Report For the financial year ended 30 June 2018

Reporting period - 1 July 2017 to 30 June 2018 (Previous corresponding period - 1 July 2016 to 30 June 2017)

### Name of entity

#### **ABN**

79 104 795 922	
----------------	--

### FINANCIAL YEAR ENDED ("CURRENT PERIOD")

### **30 JUNE 2018**

#### RESULTS FOR ANNOUNCEMENT TO THE MARKET

	Change	Change in Value \$	%	То
Revenue from ordinary activities	Up	\$323,771	136.17%	\$561,544
Other income – interest income and R&D tax incentive	Up	\$243,162	31.18%	\$1,023,152
Loss from ordinary activities after tax attributable to members	Up	\$473,858	23.47%	\$2,492,491

#### **Dividends**

It is not proposed to pay a dividend (2017: No dividend proposed).

There are no franked dividend or distribution reinvestment plans in operation and there have been no dividend or distribution payments during the financial year ended 30 June 2018 (2017: Nil).

### **Net Tangible Assets per security**

As at 30 June 2018: 0.41 cents

As at 30 June 2017: 0.22 cents

### COMMENTARY ON THE RESULTS FOR THE YEAR AND SIGNIFICANT INFORMATION

### **Results of operations**

### **Operating Results**

The consolidated loss of the Group for the financial year after providing for income tax amounted to \$2,492,491 (2017: loss of \$2,018,633).

### **Results of operations**

The Company recognised net revenue totalling \$561,544 (2017: \$237,773) during the financial year from licence income received and the sale of products.

Other income increased from \$779,990 to \$1,023,152 mainly due to the R&D tax incentive income receivable during the year in line with the increased R&D activities.

These have been negated by the increased in operating expenses incurred of \$3,753,550 (2017: \$2,969,195) to arrive at a loss before income tax which has increased to \$2,492,491 (2017: \$2018,633) as a result of amongst others, the following:

- increased external research and development (R&D) expenses \$875,146 (2017: \$585,001) as a result of the increased R&D activities during the year;
- increased business development expenses \$236,719 (2017: \$176,274) as a result
  of increased marketing and business development activities, i.e. trade shows carried
  out in the USA and European Union;
- higher share based payment expenses \$124,137 (2017: \$86,748) from the additional performance rights issued to employees during the year; and
- higher employee benefits expenses \$1,439,055 (2017: \$1,173,209) a result of annual salary increment and bonus payment to selected employees for performance achievements.

#### **Acquisition and Divestment**

During the year, there have been no entities over which control has been gained or lost during the year ended 30 June 2018.

### **Capital structure**

In July 2017, the Company announced the completion of a 1 for 3 non-renounceable rights issue at an issue price of \$0.028 per ordinary share and its associated top up facility (2017 Rights Issue) together with a subsequent placement to sophisticated and professional investors. This resulted in a successful capital raising of \$3.434 million.

#### **Events after Balance Date**

There were no other matters or circumstances that have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of these operations or the state of affairs of the Group in future financial years.

### **Audit**

This preliminary final report is based on the attached consolidated financial statements for the year ended 30 June 2018 which are in the process of being audited by the Company's auditors, Deloitte Touche Tohmatsu. The audit report will be made available with the Company's financial report as part of the Company's Annual Report which is still to be completed and will be released during September 2018.

Mr Andrew McLellan

Managing Director and CEO

28 August 2018



## **BLUECHIIP LIMITED**

ABN 79 104 795 922

Preliminary Unaudited Financial Report For the Year Ended 30 June 2018

## Bluechiip Limited ABN 79 104 795 922

### **Preliminary Unaudited Consolidated Statement of Financial Position** As at 30 June 2018

		2018	2017
	Note	\$	\$
ACCETO			
ASSETS CURRENT ASSETS			
Cash and cash equivalents	7	1,172,047	972,767
Trade and other receivables	8	1,115,669	803,171
Other current assets	9	147,583	141,023
Inventory	10	446,349	361,700
TOTAL CURRENT ASSETS		2,881,648	2,278,661
	•		
NON-CURRENT ASSETS	7	07.405	00.540
Term Deposit	7 11	27,195	26,540
Property, plant and equipment TOTAL NON-CURRENT ASSETS	''' -	124,224 151,419	78,550 105,090
TOTAL NON-CURRENT ASSETS TOTAL ASSETS	-	3,033,067	2,383,751
TOTAL ASSETS	-	3,033,007	2,303,731
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	12	643,845	1,066,835
Interest-bearing loans and borrowings	13	600,000	619,469
Employee benefits	14	79,896	59,626
TOTAL CURRENT LIABILITIES		1,323,741	1,745,930
NON-CURRENT LIABILITIES			
Employee benefits	14	79,609	40,681
TOTAL NON-CURRENT LIABILITIES		79,609	40,681
TOTAL LIABILITIES	-	1,403,350	1,786,611
NET ASSETS		1,629,717	597,140
NET AGGETO	=	1,023,717	337,140
EQUITY			
Issued capital	15	26,316,085	22,856,944
Reserves		4,871,034	4,805,107
Accumulated losses	<u>-</u>	(29,557,402)	(27,064,911)
TOTAL EQUITY	<u>-</u>	1,629,717	597,140

The above preliminary unaudited consolidated statement of financial position should be read in conjunction with the accompanying notes and the full financial report for the year ended 30 June 2017.

## Bluechiip Limited ABN 79 104 795 922

### Consolidated Statement of Profit or Loss and Other Comprehensive Income For the Year Ended 30 June 2018

	Note	2018 \$	2017 \$
Revenue from operating activities	3	561,544	237,773
Cost of sales Other income	7	(323,636) 1,023,152	(67,201) 779,990
Employee benefits expense	1	(1,439,055)	(1,173,209)
Superannuation		(115,869)	(97,520)
Share based payment expense	17	(124,137)	(86,748)
Business development		(236,719)	(176,274)
Depreciation	5 (b)	(19,185)	(19,358)
Research and Development		(875,146)	(585,001)
Patent costs		(78,568)	(88,375)
Consultancy fees		(31,314)	(37,091)
Travel and accommodation		(76,914)	(63,520)
Occupancy costs		(65,945)	(62,253)
Legal and professional fees Finance costs	5 (a)	(273,152) (59,393)	(229,408) (66,666)
Other expenses	5 (c)	(358,154)	(283,772)
Other expenses	3 (0)	(556, 154)	(200,112)
Loss before income tax		(2,492,491)	(2,018,633)
Income tax			
Net loss after income tax		(2,492,491)	(2,018,633)
Other comprehensive income		_	-
Total comprehensive loss for the year		(2,492,491)	(2,018,633)
-			
Earnings per share Basic losses per share (cents) Diluted losses per share (cents)	6 6	(0.64) (0.64)	(0.73) (0.73)

The above preliminary unaudited consolidated statement of financial position should be read in conjunction with the accompanying notes and the full financial report for the year ended 30 June 2017.

ABN 79 104 795 922

## Consolidated Statement of Changes in Equity For the Year Ended 30 June 2018

	Note	Ordinary Shares \$	Employee Equity Benefits Reserve \$	Accumulated Losses \$	Total \$
		·	•		· · ·
At 1 July 2017 Transactions with owners in		22,856,944	4,805,107	(27,064,911)	597,140
their capacity as owners:	45(-)	3,434,488	(58,210)		3,376,278
<ul><li>Shares issued during the year</li><li>Transaction costs on share</li></ul>	15(a)		(56,210)	-	
issue	15(a)	(33,557)	-	-	(33,557)
- Share-based payment expense		58,210	124,137	-	182,347
		3,459,141	65,927	-	3,525,068
Comprehensive income:	-				
- Loss for the year		-	-	(2,492,491)	(2,492,491)
- Other comprehensive income		-	-	-	-
- Total comprehensive loss attributable to members of the entity		-	-	(2,492,491)	(2,492,491)
At 30 June 2018	-	26,316,085	4,871,034	(29,557,402)	1,629,717
	Note	Ordinary Shares	Employee Equity Benefits Reserve	Accumulated Losses	Total
		\$	\$	\$	\$
At 1 July 2016  Transactions with owners in their capacity as owners:		21,373,748	4,718,359	(25,046,278)	1,045,829
<ul><li>Shares issued during the year</li><li>Transaction costs on share</li></ul>	15(a)	1,555,552	-	-	1,555,552
issue	15(a)	(72,356)	<u>-</u>	-	(72,356)
- Share-based payment expense		-	86,748	-	86,748
		1,483,196	86,748	-	1,569,944
Comprehensive income:	г			(=	<u> </u>
Loss for the year		-	-	(2,018,633)	(2,018,633)
Other comprehensive income					
	_	-	-	- (0.040.000)	- (0.040.000)
Total comprehensive loss attributable to members of the entity		-	-	(2,018,633)	(2,018,633)
Total comprehensive loss attributable to members of the	-	22,856,944	4,805,107	(2,018,633)	(2,018,633)

The above preliminary unaudited consolidated statement of changes in equity should be read in conjunction with the accompanying notes and the full financial report for the year ended 30 June 2017.

ABN 79 104 795 922

### Consolidated Statement of Cash Flows For the Year Ended 30 June 2018

	511,650	262,190
	(3,730,947)	(2,572,949)
	22,648	5,313
	(54,740)	(51,342)
	·	674,677
16	(2,475,885)	(1,682,111)
	(45,428)	(4,214)
	(45,428)	(4,214)
	0.700.040	4 400 000
	2,788,019	1,488,296
	- (E7 063)	646,919
	,	(35,317)
	(9,463)	(2,200)
7	_	(26,540)
,	600 000	600,000
	,	(500,000)
	2,720,593	2,171,158
	199,280	484,833
	972 767	487,934
_	0,2,,0,	101,001
7	1,172,047	972,767
	7	(3,730,947) 22,648 (54,740) 775,504  16 (2,475,885)  (45,428) (45,428)  2,788,019 - (57,963) (9,463)  7 - 600,000 (600,000) 2,720,593  199,280 972,767

The above preliminary unaudited consolidated statement of changes in equity should be read in conjunction with the accompanying notes and the full financial report for the year ended 30 June 2017.

ABN 79 104 795 922

Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

### **Bluechiip Limited**

ABN 79 104 795 922

### **Notes to the Preliminary Unaudited Consolidated Financial Statements**

#### **Note 1 Corporate Information**

The preliminary unaudited consolidated financial report of Bluechiip Limited for the year ended 30 June 2018 was authorised for issue in accordance with a resolution of the Directors on 28 August 2018.

Bluechiip Limited (the Parent) is a company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Stock Exchange.

The nature of the operations and principal activities of the Group during the year was the development and commercialisation of a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

### Note 2 Summary of Significant Accounting Policies

### **Basis of Preparation**

The consolidated financial statements have been prepared on the basis of historical cost. Historical cost is generally based on the fair values of the consideration given in exchange for goods and services. All amounts are presented in Australian dollars, unless otherwise noted.

### Note 3 Revenue from operating activities

	2018 \$	2017 \$
	Ψ	Ψ
Gross revenue from sale of product & licence income		
- Sale of product	433,795	140,439
- Licence income	153,007	116,755
	586,802	257,194
Less: Trade discount	25,258	(19,421)
Revenue from operating activities	561,544	237,773

ABN 79 104 795 922

### Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

### Note 4 Other Income

Note 4 Other income		
	2018 \$	2017 \$
Other revenue		
- Interest income	22,648	5,313
- R&D tax incentive/concession - Insurance recoverable	1,000,504	774,677
Total other income	1,023,152	779,990
Note 5 Expenses		
	2018	2017
	\$	\$
(a) Finance costs		
Interest expense	50,030	52,666
Debt establishment fee (refer Note 17 for further detail)	9,363	12,000
Quarterly service fee for R&D Advance Facility	-	2,000
Total finance costs	59,393	66,666
(b) Depreciation		
Depreciation of property, plant and equipment	19,185	19,358
Total	19,185	19,358
(c) Other Expenses:	00.000	00,000
Share registry, administration and secretarial Insurance	68,383 44,402	66,902 37,974
Advertising and Branding	110,979	80,380
Conference and seminar	2,754	-
Telecommunications	17,362	17,356
Membership and subscriptions	8,100	3,729
Others	106,174	77,431
Total Other Expenses	358,154	283,772
Note 6 Earnings per share		
Earnings/(loss) used to calculate basic and dilutive EPS	(2,492,491)	(2,018,633)
For basic and diluted EPS		
Weighted average number of ordinary shares outstanding		
during the year – No. used in calculating basic EPS	386,632,392	276,627,524
	, ,	, ,-

As the Group incurred a loss during the year, the impacts of performance rights were anti-dilutive and as such, basic and diluted EPS are the same amount.

ABN 79 104 795 922

## Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

### Note 7 Cash and Cash Equivalents & Term Deposit

	2018 \$	2017 \$
Current assets – Cash and Cash Equivalents Cash at bank (a)	1,172,047	972,767
Non-current assets Term Deposit (b)	27,195	26,540

<sup>(</sup>a) Cash at bank at end of previous financial year includes application money held in trust which relates to subscription money from the Rights Issue and Placement launched in June 2017 pending completion and new ordinary shares in the Company to be issued. Please refer to Note 12 for further details.

(b) Term Deposit with a bank held as security for a credit card facility.

Note 8 Current assets - Trade and Other Receivables	2018 \$	2017 \$
Trade receivables R&D tax off-set receivable	115,669 1,000,000 1,115,669	28,171 775,000 803,171
(a) The ageing analysis of trade receivables is 0-30 days 31-60 days 61-90 days (past due not impaired)	114,882 - - - 797	23,853 589 -
91+ days (past due not impaired) Total Trade and other receivables		3,729 28,171

Debts over 90 days are individually assessed for impairment. As at the date of this report, the Group deems these individually recoverable.

Note 9 Other current assets	2018 \$	2017 \$
Prepayment Deposit (a)	33,653 116.650	24,373 116,650
Doposit (a)	147,583	141,023

<sup>(</sup>a) The deposit represents the balance of a supplier payment for the purchase of raw materials to manufacture the Company's Matchbox $^{\text{TM}}$  readers.

ABN 79 104 795 922

### Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

Note 10 Inventory	2018 \$	2017 \$
Raw materials	286,218	235,278
Finished goods	221,722	188,013
Provision of net realisable value - Finished Goods	(61,591)	(61,591)
Total inventory	446,349	361,700

Management has to exercise significant judgement in estimating the net realisable value of inventory which includes estimating future sales quantities and selling prices. These estimates are based on the current contracts in place by the Company and given the application of the technology is deemed reasonable. Management assess the classification of inventory based on forward sales growth and expect to realise the inventory in the next twelve months.

Note 11 Non-current assets - Property, Plant and Equipment	2018 \$	2017 \$
Technical equipment and tools at cost	290,574	235,060
Accumulated depreciation  Total technical equipment and tools	(184,001) 106,573	(170,658) 64,402
Furniture, fixtures and fittings at cost Accumulated depreciation	18,876 (13,104)	18,876 (12,090)
Total furniture, fixtures and fittings	5,772	6,786
Computer & office equipment at cost Accumulated depreciation	119,064 (107,185)	109,719 (102,357)
Total computer & office equipment	11,879	7,362
Total property, plant and equipment	124,224	78,550

ABN 79 104 795 922

Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

Note 11 Non-current assets - Property, Plant and Equipment (continued)

(a)	Movem	ents in	Carrying	Amounts

Consolidated	Technical Equipment and Tools \$	Furniture, Fixtures and Fittings \$	Computer & Office Equipment \$	Total \$
Balance at 30 June 2018				_
Balance at the beginning of year	64,402	6,786	7,362	78,550
Additions	55,514	-	9,345	64,859
Depreciation	(13,343)	(1,014)	(4,828)	(19,185)
Carrying amount at the end of 30 June 2018	106,573	5,772	11,879	124,224

Consolidated	Technical Equipment and Tools \$	Furniture, Fixtures and Fittings \$	Computer & Office Equipment \$	Total \$
Balance at 30 June 2017				
Balance at the beginning of year	72,493	7,087	8,569	88,149
Additions	6,000	720	3,039	9,759
Depreciation	(14,091)	(1,021)	(4,246)	(19,358)
Carrying amount at the end of		· ,	· ,	
30 June 2017	64,402	6,786	7,362	78,550

2018 \$	2017 \$
546,832	368,131
62,222	51,785
34,791	-
· -	646,919
643,845	1,066,835
	\$ 546,832 62,222 34,791

- (a) The trade payables as at 30 June 2018 includes directors' fee owing of \$9,750 (2017: \$7,833).
- (b) The unearned income relates to money received from customers for licence income to be recognised in the following month and delivery of products not fulfilled at end of financial year.
- (c) The application money held in trust relates to subscription money received from shareholders and investors for the Rights Issue and Placement launched in June 2017 which were subsequently completed with new ordinary shares in the Company issued.

ABN 79 104 795 922

## Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

Note 13 Interest-bearing loans and borrowings	2018 \$	2017 \$
CURRENT		
R&D Tax Prepayment Loan (a)	600,000	600,000
Directors & Officers premium funding	-	19,469
Total Interest-bearing liabilities	600,000	619,469

Due to the short-term nature of these payables, their carrying value is assumed to approximate their fair value

(a) Relates to a R&D Advance Facility from R&D Capital Partners Pty Ltd (R&D Capital) secured by R&D tax incentive 2017/2018 to be received. In prior financial year, similar facility was obtained with R&D Capital of \$600,000 (2016/2017 Advance). The 2016/2017 Advance was secured and fully settled during the current financial year by the R&D tax incentive 2016/2017. An establishment fee of \$7,500 was incurred for the R&D Advance Facility during the financial year (2017: Nil). An interest rate of 15% (2017:15%) per annum is calculated and payable monthly on the drawn down amount of the R&D Advance Facility.

Note 14 Employee Benefits	2018 \$	2017 \$
CURRENT Annual Leave provision	79,896	59,626
NON-CURRENT Long Service Leave provision	79,609	40,681
TOTAL PROVISIONS	159,505	100,307
Note 15 Issued Capital	2018 \$	2017 \$
397,033,377 (2017: 271,810,092) Ordinary shares Less: Capitalised share issue costs	27,902,682 (1,586,597) 26,316,085	24,409,984 (1,553,040) 22,856,944
(a) Ordinary shares At the beginning of the reporting year Issue of ordinary shares Less: Capitalised share issue costs	22,856,944 3,492,698 (33,557) 26,316,085	21,373,748 1,555,552 (72,356) 22,856,944

ABN 79 104 795 922

## Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

#### **Note 15 Issued Capital (continued)**

Shares issued during the year were in relation to the following:

- 25,693,407 shares issued (\$719,415) pursuant to 2017 Rights Issue entitlement
- 88,018,307 shares (\$2,464,513) issued pursuant to shortfall shares placed with professional and sophisticated investors pursuant to 2017 Shortfall Placement
- 20,000 shares (\$560) issued as commission in connection with the 2017 Rights Issue.
- 8,928,571 shares (\$250,000) issued to a non-executive director as part of the shortfall shares subscribed in the 2017 Rights Issue pursuant to shareholders approval at the 2017 AGM
- 1,375,000 shares issued to CEO, Andrew McLellan pursuant to exercise of CS Rights Tranche 1 Performance Rights 2015 and Tranche 1 Performance Rights 2016.
- 1,188,000 shares issued to eligible employees upon exercise of the Tranche 1 Performance Rights 2016.

(b) Number of Ordinary Shares	2018 No.	2017 No.
At the beginning of the reporting year Shares issued during the year:	271,810,092	201,377,647
- Issue of ordinary shares	125,223,285	70,432,445
Total issued and fully paid ordinary shares	397,033,377	271,810,092

Ordinary shares have no par value. There is no limit to the authorised share capital of the Company.

Ordinary shares participate in dividends and the proceeds on winding up of the parent entity in proportion to the number of shares held.

At the shareholders meetings, each ordinary share is entitled to one vote when a poll is called; otherwise each shareholder has one vote on a show of hands.

At 30 June 2018, there were no options outstanding (2017: Nil).

A total 3,000,000 (2017:3,000,000) and 4,000,000 (2017:4,000,000) performance rights were granted in July 2017 to Andrew McLellan and employees respectively as part of the Variable Compensation – LTI which entitle both Andrew McLellan and the employees to acquire one fully paid share in the Company for a nil exercise price (Performance Rights). Further details of the performance rights and the terms are set out in the Variable Compensation – Long-term Incentive section of the remuneration report.

#### (c) Capital Management

Management controls the capital of the Group in order to ensure that the Company can fund its operations and continue as a going concern. The Group's debt and capital includes share capital and financial liabilities, supported by financial assets. There is no externally imposed capital requirements.

Management effectively manages the Group's capital by assessing the Company's financial risk and adjusting its capital structure in response to changes in these risks and in the market. There have been no changes in the strategy adopted by management.

ABN 79 104 795 922

## Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

#### Note 16 Cash Flow Statement Reconciliation

Reconciliation of Net Loss after Tax to Net Cash Flows used in operating activities

	2018 \$	2017 \$
Net loss	(2,492,491)	(2,018,633)
Non-cash Flows in Loss - Depreciation - Share based payment expense - Shares issue in lieu of cash bonus payment to employees - Shares issue in lieu of payment to supplier	19,185 124,137 - -	19,358 86,748 49,900 12,106
Changes in Assets and Liabilities  - (Increase)/decrease in trade and other receivables  - (Increase)/decrease in other assets  - (Increase)/decrease in inventory  - (Decrease)/increase in trade, other payables and deferred revenue  - (Decrease)/increase in employee benefits	(312,498) (6,561) (84,649) 217,794 59,198 (2,475,885)	(77,407) 32,530 20,211 166,315 26,761 (1,682,111)

#### **Note 17 Share-based Payment Plans**

#### **Expenses Arising From Share-based Payment Transactions**

The performance rights expense under the Performance Rights Plan 2017 has been determined based on the fair values of the performance rights granted to Directors and officers calculated at grant date using a hybrid trinomial option pricing model with a relative TSR hurdle. The hybrid trinomial option pricing model with TSR hurdle uses a combination of Monte Carlo Simulation and a trinomial lattice to model the performance of the Company's shares and the individual shares within the selected peer group, taking into account their individual volatilities and correlations.

	2018 \$	2017 \$
Performance Rights Plan expense during the year - Performance Rights Plan 2015 - Performance Rights Plan 2016 - Performance Rights Plan 2017	5,795 40,555 77,787	18,370 68,378
	124,137	86,748

#### **Fair Value of Performance Rights**

The fair value of the performance rights granted to the CEO in the table below has been calculated at grant date using the hybrid trinomial option pricing model with TSR hurdle. The model uses a combination of Monte Carlo Simulation and a trinomial lattice to model the performance of the Company's shares and the individual shares within the selected peer group, taking into account their individual volatilities and correlations.

ABN 79 104 795 922

### Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

2018

During the financial year, the following performance rights were granted to the CEO, Andrew McLellan and employees of the Company:

Number and Recipient of Performance Rights	Grant Date	Vesting Date/ Exercise Expiry date	Fair Value Per Performance Right	Exercise Price	Price of Shares on Grant Date	Risk Free interest Rate	Estimated Volatility
3,000,000 to Andrew McLellan comprising:							
Tranche 1 -1,000,000	1 July 2017	30 Aug 2018/	\$0.0186	Nil	\$0.028	1.53%	90%
Tranche 2 -1,000,000	1 July 2017	30 Aug 2019/	\$0.0207	Nil	\$0.028	1.66%	90%
Tranche 3 -1,000,000	1 July 2017	30 Aug 2020/	\$0.0245	Nil	\$0.028	1.86%	90%
4,000,000 to employees comprising:							
Tranche 1 -1,333,333	1 July 2017	30 Aug 2018/	\$0.0189	Nil	\$0.028	1.57%	90%
Tranche 2 -1,333,333	1 July 2017	30 Aug 2019/	\$0.0218	Nil	\$0.028	1.73%	90%
Tranche 3 -1,333,333	1 July 2017	30 Aug 2020/	\$0.0230	Nil	\$0.028	1.94%	90%

Other than the Performance Rights granted to the CEO, Andrew McLellan and employees as set out above, no options were issued to Directors or other KMP during the financial year ended 30 June 2018.

ABN 79 104 795 922

### Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

2017

No options were issued to/or exercised by Directors, employees or other KMP during the financial year ended 30 June 2017.

Number and recipient of Performance Rights	Grant date	Vesting Date/ Exercise Expiry date	Fair value per Performance Right	Exercise price	Price of shares on grant date	Risk free interest rate	Estimated volatility
3,000,000 to Andrew McLellan comprising:							
• Tranche 1 -1,000,000	1 July.2016	30.08.2017/ 31.12.2017	\$0.0168	Nil	\$0.022	1.49%	100%
• Tranche 2 -1,000,000	1 July 2016	30.08.2018/ 31.12.2018	\$0.0186	Nil	\$0.022	1.46%	100%
• Tranche 3 -1,000,000	1 July 2016	30.08.2019/ 31.12.2019	\$0.0201	Nil	\$0.022	1.51%	100%
4,000,000 to employees comprising:							
• Tranche 1 -1,333,333	1 July 2016	30.08.2017/ 31.12.2017	\$0.0168	Nil	\$0.022	1.49%	100%
• Tranche 2 -1,333,333	1 July 2016	30.08.2018/ 31.12.2018	\$0.0186	Nil	\$0.022	1.46%	100%
• Tranche 3 -1,333,333	1 July 2016	30.08.2019/ 31.12.2019	\$0.0201	Nil	\$0.022	1.51%	100%

Other than the Performance Rights granted to the CEO, Andrew McLellan and employees as set out above, no options were issued to Directors or other KMP during the financial year ended 30 June 2017.

ABN 79 104 795 922

## Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

Note18 Commitments	2018 \$	2017 \$
(a) Operating Lease Commitments	-	
Non-cancellable operating leases contracted for:		
Payable - minimum lease payments: - not later than 12 months	36,050 36,050	35,000 35,000

The above lease commitments are in respect of office premises rental.

#### (b) Contractual Commitments

Subsequent to 30 June 2018, the Company has purchase orders made in 2014 with a foreign supplier which remains unfulfilled with purchase cost totalling \$260,348 (USD192,423) (2017: \$249,926 or USD192,243) for the development and production of chips.

### **Note 19 Contingencies**

The Company has no contingent liabilities or contingent assets as at 30 June 2018.

### Note 20 Events After the Balance Sheet Date

There were no other matters or circumstances that have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of these operations or the state of affairs of the Group in future financial years.

ABN 79 104 795 922

### Notes to the Consolidated Financial Statements (continued) For the Year Ended 30 June 2018

### **Note 21 Controlled Entities**

	Country of Incorporation	Percentage Owned (%)* 2018	Percentage Owned (%)* 2017
Parent Entity:	•		
Bluechiip Limited	Australia		
Subsidiaries of Parent Entity:			
Bluechiip, Inc.(a)	United States	100%	100%
Bluechiip Holdings, Inc.(a)	United States	100%	100%

### Note 22 Parent entity information

	2018 \$	2017 \$
Information relating to Bluechiip Limited		
Current assets	2,881,648	2,278,661
Total assets	3,033,067	2,383,751
Current liabilities	1,323,741	1,745,930
Total liabilities	1,403,350	1,786,611
Issued capital	26,316,085	22,856,944
Reserves	4,871,034	4,805,107
Accumulated losses	(29,557,402)	(27,064,911)
Total shareholder's equity	1,629,717	597,140
Loss of the parent entity	(2,492,491)	(2,018,633)
Total comprehensive loss of the parent entity	(2,492,491)	(2,018,633)

<sup>\*</sup> Percentage of voting power is in proportion to ownership
(a) These companies (which are dormant) are in the process of dissolution as the Directors opine that the subsidiaries are not required at this moment.